APLLTD — Alembic Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- IN₹149.41bn
- IN₹161.55bn
- IN₹73.45bn
India's Alembic Pharma posts lower Q3 profit on weak domestic demand
Brief: Alembic Pharma Q3 Consol Profit 1.38 Billion Rupees
Brief: Alembic Pharmaceuticals Receives USFDA Final Approval For Divalproex Sodium Capsules
Brief: Alembic Pharmaceuticals Passes Anvisa GMP Audit For API-II Facility
Brief: Alembic Pharmaceuticals Dissolves Six Step-Down Subsidiaries
Brief: Alembic Pharmaceuticals Gets USFDA Tentative Approval For Olopatadine Hydrochloride Ophthalmic
Indian drugmaker Alembic Pharma misses Q2 profit view as US sales growth slows
Brief: Alembic Pharmaceuticals Says Completion Of USFDA Inspection At Co's Oncology Formulation Facility
India's Alembic Pharma rises on US FDA nod for eye treatment drug
India's Alembic Pharmaceuticals up on FDA approval for seizure treatment tablets
Brief: Alembic Pharmaceuticals Gets USFDA Final Approval For Lamotrigine Extended-Release Tablets
Brief: Alembic Pharma Says USFDA Approval For Paliperidone Extended-Release Tablets
Pharma firm Granules India plunges after USFDA scrutiny
India's Alembic Pharma gains after US FDA approval for drug
India's Alembic Pharma rises after US FDA approves skin disease drug
Brief: Alembic Pharmaceuticals Gets USFDA Final Approval For Dabigatran Etexilate Capsules
India's Zydus Lifesciences Q1 profit beats estimates on strong US demand
Indian drugmaker Alembic Pharma posts Q1 profit rise on strong US sales
Brief: Alembic Pharma Q1 Consol Profit 1.35 Bln Rupees